少ない教室員で呼吸器疾患全般の診療を行いながらCOVID-19にも対応し、この1年過酷な時期もありましたが、時間を見つけて学術活動を行ってきました。新メンバーになって初年度、以下のような臨床系論文を紙面発表しました。これからも国内外との共有財産を発信出来るよう、皆で精進してまいります。
1. A 63-year-old woman with an acute exacerbation of interstitial pneumonia. Kinoshita Y, et al. Chest, in press
2. Severe and progressive platythorax disproportionate to lung fibrosis: A rare variant of idiopathic pleuroparenchymal fibroelastosis. Ikeda T, et al. Respir Med Case Rep, 2021.
3. 胸腺腫に合併した細胞性/破壊性閉塞性細気管支炎の1例. 上田裕介、他. 日呼吸会誌, 2021.
4. Feasibility, utility, and safety of transbronchial cryobiopsy for interstitial lung diseases in Japan. Ikeda T, et al. Multidiscip Respir Med, 2021.
5. Aspergillus niger-pulmonary aspergillosis in an immunocompetent woman. Otsuka R, et al. Intern Med doi: 10.2169/internalmedicine.6057-20, 2021.
6. 当科における肺胞蛋白症の経験. 池田貴登、他. 日肺サーファクタント界面医会誌 51: 34-35, 2021.
7. 一目瞭然！目で診る症例. 木下義晃、他. 日内会誌 110(1): 137-139, 2021.
8. Role of alveolar collapse in idiopathic pleuroparenchymal fibroelastosis. Kinoshita Y, et al. Sarcoidosis Vasc Diffuse Lung Dis 37(2): 212-217, 2020.
9. Tattoo-induced systemic sarcoidosis. Kushima H, et al. BMJ Case Rep 13: e237723, 2020.
10. The pathogenesis and pathology of idiopathic pleuroparenchymal fibroelastosis. Kinoshita Y, et al. Histol Histopathol doi:10.14670/HH-18-289, 2020.
11. Physiological criteria are useful for the diagnosis of idiopathic pleuroparenchymal fibroelastosis. Ikeda T, et al. J Clin Med 9(11): 3761, 2020.
12. Serum latent transforming growth factor-β binding protein 4 as a novel biomarker for idiopathic pleuroparenchymal fibroelastosis. Kinoshita Y, et al. Respir Med 171: 106077, 2020.
13. Histological difference between sarcoidosis and lung cancer-related sarcoid reaction. Kinoshita Y, et al. Respir Investig 58: 421-424 2020.
